Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metformin + sulphonylurea is a combination therapy used to treat type 2 diabetes mellitus. It combines two different mechanisms of action to control blood glucose levels. Metformin (a biguanide) decreases glucose production in the liver, slows intestinal absorption of glucose, and improves insulin sensitivity. Sulphonylureas (such as glipizide or glyburide) stimulate the pancreas to release more insulin. This combination is typically prescribed when diet, exercise, and monotherapy with either agent alone fail to achieve adequate glycemic control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metformin + sulphonylurea.